123). It is noteworthy that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for lack of Gls in MYC-induced mouse liver tumours40. This suggests that GLS2 could confer resistance to GLS1-particular inhibitors, like the allosteric inhibitor BPTES or CB-839, which resistance may be hypothetically prevented by the https://tanshinone-iia33219.blogzag.com/73494609/detailed-notes-on-recombinant